Terrance P. Coyne

CIK: 0001814876

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)35 (79.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (15.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (4.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RPRX

Royalty Pharma plc

Officer

Discretionary Trading P&L

Holdings

Transaction History (44 total)

RPRX
Royalty Pharma plc
Aug 13, 2026
Sale(S)
Indirect
1.8K shares at avg. $59.14$105K
RPRX
Royalty Pharma plc
Aug 13, 2026
Sale(S)
Indirect
9.2K shares at avg. $58.59$541K
RPRX
Royalty Pharma plc
Aug 7, 2026
Gift(G)
Class E Ordinary Shares
Indirect
18.5K shares-
RPRX
Royalty Pharma plc
Aug 5, 2026
Award(A)
Indirect
11K shares-
RPRX
Royalty Pharma plc
May 26, 2026
Sale(S)
Indirect
64.4K shares at avg. $53.98$3.5M
RPRX
Royalty Pharma plc
May 6, 2026
Award(A)
Indirect
24.3K shares-
RPRX
Royalty Pharma plc
Apr 28, 2026
Sale(S)
Indirect
32.9K shares at avg. $49.78$1.6M
RPRX
Royalty Pharma plc
Apr 28, 2026
Sale(S)
Indirect
1.9K shares at avg. $49.78$93K
RPRX
Royalty Pharma plc
Apr 1, 2026
Sale(S)
Indirect
32.9K shares at avg. $48.33$1.6M
RPRX
Royalty Pharma plc
Apr 1, 2026
Sale(S)
Indirect
1.9K shares at avg. $48.33$91K
RPRX
Royalty Pharma plc
Mar 23, 2026
Sale(S)
Indirect
1.9K shares at avg. $45.53$85K
RPRX
Royalty Pharma plc
Mar 23, 2026
Sale(S)
Indirect
32.9K shares at avg. $45.53$1.5M
RPRX
Royalty Pharma plc
Mar 2, 2026
Sale(S)
Indirect
583 shares at avg. $47.01$27K
RPRX
Royalty Pharma plc
Mar 2, 2026
Sale(S)
Indirect
1.3K shares at avg. $46.67$60K
RPRX
Royalty Pharma plc
Mar 2, 2026
Sale(S)
Indirect
10.4K shares at avg. $47.01$490K
RPRX
Royalty Pharma plc
Mar 2, 2026
Sale(S)
Indirect
22.5K shares at avg. $46.67$1.0M
RPRX
Royalty Pharma plc
Feb 23, 2026
Sale(S)
Indirect
32.9K shares at avg. $45.32$1.5M
RPRX
Royalty Pharma plc
Feb 23, 2026
Sale(S)
Indirect
1.9K shares at avg. $45.32$85K
RPRX
Royalty Pharma plc
Feb 11, 2026
Award(A)
Indirect
26.6K shares-
RPRX
Royalty Pharma plc
Feb 4, 2026
Sale(S)
Indirect
1.1K shares at avg. $43.29$47K
RPRX
Royalty Pharma plc
Feb 4, 2026
Sale(S)
Indirect
19.1K shares at avg. $43.29$826K
RPRX
Royalty Pharma plc
Feb 3, 2026
Sale(S)
Indirect
6.2K shares at avg. $42.84$265K
RPRX
Royalty Pharma plc
Feb 3, 2026
Sale(S)
Indirect
108.8K shares at avg. $42.84$4.7M
RPRX
Royalty Pharma plc
Feb 2, 2026
Sale(S)
Indirect
5.8K shares at avg. $42.08$246K
RPRX
Royalty Pharma plc
Feb 2, 2026
Sale(S)
Indirect
102.6K shares at avg. $42.08$4.3M

		Type	Shares	Price		Ownership
Aug 13, 2026	RPRX Royalty Pharma plc	Sale(S)	1,772	$59.14	$104,799	Indirect
Aug 13, 2026	RPRX Royalty Pharma plc	Sale(S)	9,230	$58.59	$540,752	Indirect
Aug 7, 2026	RPRX Royalty Pharma plc	Gift(G) Class E Ordinary Shares	18,500	-	-	Indirect
Aug 5, 2026	RPRX Royalty Pharma plc	Award(A)	11,002	-	$0	Indirect
May 26, 2026	RPRX Royalty Pharma plc	Sale(S)	64,399	$53.98	$3,476,116	Indirect
May 6, 2026	RPRX Royalty Pharma plc	Award(A)	24,263	-	$0	Indirect
Apr 28, 2026	RPRX Royalty Pharma plc	Sale(S)	32,916	$49.78	$1,638,506	Indirect
Apr 28, 2026	RPRX Royalty Pharma plc	Sale(S)	1,875	$49.78	$93,335	Indirect
Apr 1, 2026	RPRX Royalty Pharma plc	Sale(S)	32,916	$48.33	$1,590,890	Indirect
Apr 1, 2026	RPRX Royalty Pharma plc	Sale(S)	1,875	$48.33	$90,622	Indirect
Mar 23, 2026	RPRX Royalty Pharma plc	Sale(S)	1,875	$45.53	$85,366	Indirect
Mar 23, 2026	RPRX Royalty Pharma plc	Sale(S)	32,916	$45.53	$1,498,623	Indirect
Mar 2, 2026	RPRX Royalty Pharma plc	Sale(S)	583	$47.01	$27,409	Indirect
Mar 2, 2026	RPRX Royalty Pharma plc	Sale(S)	1,292	$46.67	$60,304	Indirect
Mar 2, 2026	RPRX Royalty Pharma plc	Sale(S)	10,429	$47.01	$490,314	Indirect
Mar 2, 2026	RPRX Royalty Pharma plc	Sale(S)	22,487	$46.67	$1,049,507	Indirect
Feb 23, 2026	RPRX Royalty Pharma plc	Sale(S)	32,916	$45.32	$1,491,638	Indirect
Feb 23, 2026	RPRX Royalty Pharma plc	Sale(S)	1,875	$45.32	$84,968	Indirect
Feb 11, 2026	RPRX Royalty Pharma plc	Award(A)	26,626	-	$0	Indirect
Feb 4, 2026	RPRX Royalty Pharma plc	Sale(S)	1,087	$43.29	$47,059	Indirect
Feb 4, 2026	RPRX Royalty Pharma plc	Sale(S)	19,076	$43.29	$825,853	Indirect
Feb 3, 2026	RPRX Royalty Pharma plc	Sale(S)	6,195	$42.84	$265,413	Indirect
Feb 3, 2026	RPRX Royalty Pharma plc	Sale(S)	108,759	$42.84	$4,659,584	Indirect
Feb 2, 2026	RPRX Royalty Pharma plc	Sale(S)	5,843	$42.08	$245,896	Indirect
Feb 2, 2026	RPRX Royalty Pharma plc	Sale(S)	102,581	$42.08	$4,317,009	Indirect

1-25 of 44 transactions

About Coyne Terrance P.

Coyne Terrance P. (SEC CIK 0001814876) files insider reports with the SEC as EVP & CFO of Royalty Pharma plc (RPRX).

Signal8 holds 21 ownership filings by Coyne Terrance P., all Form 4s, filed between May 9, 2025 and Aug 17, 2026. Those filings report 44 transactions, from May 8, 2025 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Coyne Terrance P.'s filings is in NEW YORK, NY.

Recent filings by Coyne Terrance P.

Aug 13, 2026: Open-market sales of RPRX shares (2 lines, Form 4, code S).
Aug 7, 2026: Gift of RPRX derivative securities (Form 4, code G).
Aug 5, 2026: Grant or award of RPRX shares (Form 4, code A).
May 26, 2026: Open-market sale of RPRX shares (Form 4, code S).
May 6, 2026: Grant or award of RPRX shares (Form 4, code A).

Other insiders filing for Royalty Pharma plc (RPRX)

Urist Marshall, EVP, Research & Investments
Bassler Bonnie L, Director
Hite Christopher, EVP & Chairman, Partnering
Legorreta Pablo G., CEO, Chairman of the Board
WEATHERMAN ELIZABETH H, Director
Norden Gregory, Director

How to read Form 4 transaction codes